Literature DB >> 31825847

A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.

Kate Lawrenson1, Marcos A S Fonseca2, Annie Y Liu2, Felipe Segato Dezem2, Janet M Lee3, Xianzhi Lin2, Rosario I Corona4, Forough Abbasi4, Kevin C Vavra4, Huy Q Dinh5, Navjot Kaur Gill6, Ji-Heui Seo7, Simon Coetzee3, Yvonne G Lin8, Tanja Pejovic9, Paulette Mhawech-Fauceglia10, Amy C Rowat6, Ronny Drapkin11, Beth Y Karlan2, Dennis J Hazelett3, Matthew L Freedman7, Simon A Gayther12, Houtan Noushmehr13.   

Abstract

Fallopian tube secretory epithelial cells (FTSECs) are likely the main precursor cell type of high-grade serous ovarian cancers (HGSOCs), but these tumors may also arise from ovarian surface epithelial cells (OSECs). We profiled global landscapes of gene expression and active chromatin to characterize molecular similarities between OSECs (n = 114), FTSECs (n = 74), and HGSOCs (n = 394). A one-class machine learning algorithm predicts that most HGSOCs derive from FTSECs, with particularly high FTSEC scores in mesenchymal-type HGSOCs (padj < 8 × 10-4). However, a subset of HGSOCs likely derive from OSECs, particularly HGSOCs of the proliferative type (padj < 2 × 10-4), suggesting a dualistic model for HGSOC origins. Super-enhancer (SE) landscapes were also more similar between FTSECs and HGSOCs than between OSECs and HGSOCs (p < 2.2 × 10-16). The SOX18 transcription factor (TF) coincided with a HGSOC-specific SE, and ectopic overexpression of SOX18 in FTSECs caused epithelial-to-mesenchymal transition, indicating that SOX18 plays a role in establishing the mesenchymal signature of fallopian-derived HGSOCs.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA-seq; SOX18; dual origins; fallopian tube secretory epithelial cell; high-grade serous ovarian cancer; machine learning; one-class logistic regression models; ovarian surface epithelial cell; single-cell RNA-seq; super enhancers; transcription factors

Year:  2019        PMID: 31825847     DOI: 10.1016/j.celrep.2019.10.122

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  15 in total

1.  Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.

Authors:  Koji Nakamura; Brett M Reid; Ann Chen; Zhihua Chen; Ellen L Goode; Jennifer B Permuth; Jamie K Teer; Jonathan Tyrer; Xiaoqing Yu; Peter A Kanetsky; Paul D Pharoah; Simon A Gayther; Thomas A Sellers; Kate Lawrenson; Florian A Karreth
Journal:  Am J Hum Genet       Date:  2021-12-28       Impact factor: 11.043

2.  The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.

Authors:  Daniele Chaves-Moreira; Marilyn A Mitchell; Cristina Arruza; Priyanka Rawat; Simone Sidoli; Robbin Nameki; Jessica Reddy; Rosario I Corona; Lena K Afeyan; Isaac A Klein; Sisi Ma; Boris Winterhoff; Gottfried E Konecny; Benjamin A Garcia; Donita C Brady; Kate Lawrenson; Patrice J Morin; Ronny Drapkin
Journal:  Sci Signal       Date:  2022-04-05       Impact factor: 9.517

3.  Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.

Authors:  Shuang Zhang; Sonia Iyer; Hao Ran; Igor Dolgalev; Shengqing Gu; Wei Wei; Connor J R Foster; Cynthia A Loomis; Narciso Olvera; Fanny Dao; Douglas A Levine; Robert A Weinberg; Benjamin G Neel
Journal:  Cancer Discov       Date:  2020-11-06       Impact factor: 39.397

Review 4.  The current landscape of single-cell transcriptomics for cancer immunotherapy.

Authors:  Puneeth Guruprasad; Yong Gu Lee; Ki Hyun Kim; Marco Ruella
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 17.579

5.  Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.

Authors:  Chloe Camille Lepage; Michaela Cora Lynn Palmer; Ally Catherina Farrell; Nicole Marie Neudorf; Zelda Lichtensztejn; Mark William Nachtigal; Kirk James McManus
Journal:  Br J Cancer       Date:  2021-03-17       Impact factor: 7.640

Review 6.  Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.

Authors:  Daria A Haręża; Jacek R Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

7.  WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.

Authors:  Sanghoon Lee; John Jun; William J Kim; Pablo Tamayo; Stephen B Howell
Journal:  Anticancer Res       Date:  2020-11       Impact factor: 2.435

8.  Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.

Authors:  Kadi Lõhmussaar; Oded Kopper; Jeroen Korving; Harry Begthel; Celien P H Vreuls; Johan H van Es; Hans Clevers
Journal:  Nat Commun       Date:  2020-05-27       Impact factor: 14.919

9.  A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.

Authors:  Pietro Lo Riso; Carlo Emanuele Villa; Gilles Gasparoni; Andrea Vingiani; Raffaele Luongo; Anna Manfredi; Annemarie Jungmann; Alessia Bertolotti; Francesca Borgo; Annalisa Garbi; Michela Lupia; Pasquale Laise; Vivek Das; Giancarlo Pruneri; Giuseppe Viale; Nicoletta Colombo; Teresa Manzo; Luigi Nezi; Ugo Cavallaro; Davide Cacchiarelli; Jörn Walter; Giuseppe Testa
Journal:  Genome Med       Date:  2020-10-30       Impact factor: 11.117

10.  High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.

Authors:  Siel Olbrecht; Pieter Busschaert; Junbin Qian; Adriaan Vanderstichele; Liselore Loverix; Toon Van Gorp; Els Van Nieuwenhuysen; Sileny Han; Annick Van den Broeck; An Coosemans; Anne-Sophie Van Rompuy; Diether Lambrechts; Ignace Vergote
Journal:  Genome Med       Date:  2021-07-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.